18889881171
Kalkine 0
countryflagUS

AAPL 196.98 1.395% MSFT 367.78 -1.0307% NVDA 101.49 -2.8711% GOOGL 151.16 -1.4152% GOOG 153.36 -1.3762% AMZN 172.61 -0.9866% META 501.48 -0.1652% AVGO 170.99 -2.0732% LLY 839.96 14.2958% TSLA 241.37 -0.0745% TSM 151.74 0.0462% V 329.61 -0.5191% JPM 231.96 1.0235% UNH 454.11 -22.3797% NVO 58.08 -7.6336% WMT 93.22 2.2261% LVMUY 110.1 1.0741% XOM 106.92 2.6202% LVMHF 559.0 1.7288% MA 517.33 0.7596%

Avax Techs Inc

Healthcare US AVXT

0.0USD
-(-%)

Last update at 2025-04-17T13:30:00Z

52 Week Range

-0.0001
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap6.42M
  • Volume0
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-5.87368M
  • Revenue TTM0.14M
  • Revenue Per Share TTM0.001
  • Gross Profit TTM 0.14M
  • Diluted EPS TTM-

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2010-12-31 2009-12-31 2008-12-31 2007-12-31 2006-12-31
Type yearly yearly yearly yearly yearly
Date 2010-12-31 2009-12-31 2008-12-31 2007-12-31 2006-12-31
Income before tax -11.99309M -19.42446M -6.48267M -6.41365M -5.35550M
Minority interest 0.00000M 0.00000M 0.00000M 0.00000M -
Net income -11.99309M -19.42446M -6.48267M -6.41365M -5.35550M
Selling general administrative 4.17M 2.76M 3.51M 2.71M 1.99M
Selling and marketing expenses - - - - -
Gross profit 0.14M 0.40M 0.65M 0.62M 0.73M
Reconciled depreciation - - - - -
Ebit -5.91614M -4.88359M -6.06604M -6.69288M -5.35550M
Ebitda - - - - -
Depreciation and amortization - - - - -
Non operating income net other 0.00000M 0.00000M 0.00000M 0.00000M -
Operating income -5.91614M -4.88359M -6.06604M -6.69288M -5.49868M
Other operating expenses 0.00000M 0.00000M 0.00000M 0.00000M -
Interest expense 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Tax provision - - - - -
Interest income - - - - -
Net interest income - - - - -
Extraordinary items 0.00000M 0.00000M 0.00000M 0.00000M -
Non recurring 0.00000M 0.00000M 0.00000M 0.00000M -
Other items 0.00000M 0.00000M 0.00000M 0.00000M -
Income tax expense 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total revenue 0.14M 0.40M 0.65M 0.62M 0.73M
Total operating expenses 6.06M 5.28M 6.72M 7.31M 0.00000M
Cost of revenue 0.00000M 0.00000M 0.00000M 7.37M 5.94M
Total other income expense net -6.07696M -14.54087M -0.41663M 0.28M 0.14M
Discontinued operations 0.00000M 0.00000M 0.00000M 0.00000M -
Net income from continuing ops -11.99309M -19.42446M -6.48267M -6.41365M -5.35550M
Net income applicable to common shares -11.99309M -19.42446M -6.48267M -6.41365M -5.35550M
Preferred stock and other adjustments 0.00000M 0.00000M 0.00000M 0.00000M -
Breakdown 2010-12-31 2009-12-31 2008-12-31 2007-12-31 2006-12-31
Type yearly yearly yearly yearly yearly
Date 2010-12-31 2009-12-31 2008-12-31 2007-12-31 2006-12-31
Total assets 0.58M 1.03M 2.67M 7.38M 3.04M
Intangible assets 0.00000M 0.00000M 0.00000M 0.20M 0.19M
Earning assets - - - - -
Other current assets 0.22M 0.20M 0.28M 0.33M 0.21M
Total liab 21.02M 22.63M 5.29M 3.99M 2.70M
Total stockholder equity -20.44088M -21.59845M -2.61834M 3.38M 0.34M
Deferred long term liab 0.00000M 0.00000M 0.00000M 0.00000M -
Other current liab 14.76M 16.09M 1.13M 0.25M 1.24M
Common stock 2.13M 0.57M 0.57M 0.57M 0.25M
Capital stock - - - - -
Retained earnings -122.28715M -110.29406M -90.73750M -84.25483M -77.84118M
Other liab 0.00000M 0.00000M 0.00000M 0.00000M -
Good will 0.00000M 0.00000M 0.00000M 0.19M 0.19M
Other assets 0.12M 0.62M 1.05M 0.00000M -
Cash 0.09M 0.03M 0.55M 5.90M 1.49M
Cash and equivalents - - - - -
Total current liabilities 21.02M 22.63M 5.29M 3.99M 2.70M
Current deferred revenue - - - - -
Net debt - - - - -
Short term debt 0.00000M 0.00000M 0.00000M 0.00000M -
Short long term debt 3.33M 1.52M 0.07M 0.42M -
Short long term debt total - - - - -
Other stockholder equity 0.38M 0.33M 0.33M 0.41M 0.48M
Property plant equipment 0.08M 0.11M 0.54M 0.74M 0.88M
Total current assets 0.39M 0.30M 1.08M 6.45M 1.98M
Long term investments 0.00000M 0.00000M 0.00000M 0.00000M -
Net tangible assets -20.44088M -21.59845M -2.61834M 3.19M 0.16M
Short term investments 0.00000M 0.00000M 0.00000M 0.00000M -
Net receivables 0.08M 0.05M 0.23M 0.21M 0.27M
Long term debt 0.00000M 0.00000M 0.00000M 0.00000M -
Inventory 0.00000M 0.00000M 0.01M 0.01M 0.01M
Accounts payable 2.37M 2.23M 2.00M 2.09M 1.46M
Total permanent equity 0.00000M 0.00000M 0.00000M 0.00000M -
Noncontrolling interest in consolidated entity 0.00000M 0.00000M 0.00000M 0.00000M -
Temporary equity redeemable noncontrolling interests 0.00000M 0.00000M 0.00000M 0.00000M -
Accumulated other comprehensive income 0.00000M 0.00000M 0.00000M 0.00000M -
Additional paid in capital 0.00000M 0.00000M 0.00000M 0.00000M -
Common stock total equity 0.00000M 0.00000M 0.00000M 0.00000M -
Preferred stock total equity 0.00000M 0.00000M 0.00000M 0.00000M -
Retained earnings total equity 0.00000M 0.00000M 0.00000M 0.00000M -
Treasury stock 0.00000M 0.00000M 0.00000M 0.00000M -
Accumulated amortization 0.00000M 0.00000M 0.00000M 0.00000M -
Non currrent assets other 0.00000M 0.00000M 0.00000M 0.00000M -
Deferred long term asset charges 0.00000M 0.00000M 0.00000M 0.00000M -
Non current assets total 0.00000M 0.00000M 0.00000M 0.00000M -
Capital lease obligations 0.00000M 0.00000M 0.00000M 0.00000M -
Long term debt total 0.00000M 0.00000M 0.00000M 0.00000M -
Breakdown 2010-12-31 2009-12-31 2008-12-31 2007-12-31 2006-12-31
Type yearly yearly yearly yearly yearly
Date 2010-12-31 2009-12-31 2008-12-31 2007-12-31 2006-12-31
Investments 0.00000M 0.00000M 0.00000M 0.00000M -
Change to liabilities -0.10953M 0.59M -0.33950M 1.20M 0.73M
Total cashflows from investing activities -0.00281M -0.01268M -0.10498M -0.12740M -0.04031M
Net borrowings 0.23M 2.31M 1.32M 1.32M -
Total cash from financing activities 3.49M 2.31M 1.32M 9.32M 9.32M
Change to operating activities -0.22141M -0.01569M 0.42M -0.12235M 0.16M
Net income -11.99309M -19.42446M -6.48267M -6.41365M -5.35550M
Change in cash 0.06M -0.52522M -5.35240M 4.42M -4.08858M
Begin period cash flow - - - - -
End period cash flow - - - - -
Total cash from operating activities -3.43980M -2.84567M -6.49161M -4.73190M -4.09385M
Issuance of capital stock - - - - -
Depreciation 0.04M 0.44M 0.29M 0.30M 0.29M
Other cashflows from investing activities 0.00000M 0.00000M 0.00000M 0.00000M -
Dividends paid 0.00000M 0.00000M 0.00000M 0.00000M -
Change to inventory 0.00000M 0.01M 0.00087M 0.00010M 0.00300M
Change to account receivables 0.00000M 0.18M -0.05942M 0.10M -0.11998M
Sale purchase of stock 1.98M 0.88M 0.10M 9.79M 9.32M
Other cashflows from financing activities 0.00000M 0.00000M 0.00000M 0.00000M -
Change to netincome 7.19M 14.46M 0.49M 0.20M 0.15M
Capital expenditures 0.00281M 0.01M 0.10M 0.13M 0.04M
Change receivables 0.00000M 0.00000M 0.00000M 0.00000M -
Cash flows other operating 0.00000M 0.00000M 0.00000M 0.00000M -
Exchange rate changes 0.00000M 0.00000M 0.00000M 0.00000M -
Cash and cash equivalents changes 0.00000M 0.00000M 0.00000M 0.00000M -
Change in working capital - - - - -
Stock based compensation - - - - -
Other non cash items - - - - -
Free cash flow - - - - -

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AVXT
Avax Techs Inc		 - -% - - - 45.03 - 9.71 -0.9863
NVO
Novo Nordisk A/S		 -4.8 7.63% 58.08 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -2.79 4.46% 59.70 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.21 0.66% 489.10 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 13.88 2.53% 563.16 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

AVAX Technologies, Inc., a development stage biopharmaceutical company, develops autologous cell vaccine technologies for the treatment of cancer. The company's product candidates that have completed phase II clinical trials include M-VAX for the treatment of melanoma and O-VAX for the treatment for ovarian cancer. It also develops LungVax for the treatment of non-small cell lung cancer. The company was formerly known as Walden Laboratories, Inc. and changed its name to AVAX Technologies, Inc. in March 1996. AVAX Technologies, Inc. was founded in 1990 and is based in Philadelphia, Pennsylvania.

Avax Techs Inc

2000 Hamilton Street, Philadelphia, PA, United States, 19130

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.